Cytosurge launches cell line engineering services based on proprietary FluidFM technology
Zurich, March 30, 2022 – Cytosurge , a global leader in precision single cell manipulation, today announced the launch of FluidFM[®] CellEDIT, a CRISPR cell line engineering service based on its FluidFM[®] technology. Genetically engineered cell lines have become an invaluable tool in biological research and drug discovery. Nobel-prize winning CRISPR technology has opened up multiple opportunities for generating genome-edited cell lines to be used as disease models, which help the understanding of the biology